March 3, 2009
Pompe Program Update from Genzyme
Supply Update In January 2009, Genzyme notified the Pompe community that we were experiencing a temporary constraint in the global
CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that it has received a complete response letter from the FDA
February 27, 2009
Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe
Amicus Therapeutics announced today that the Company has suspended enrollment for the Phase 2 clinical trial of its investigational drug
CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that the European Commission has approved the production of Myozyme® (alglucosidase
February 19, 2009
Genzyme Receives Positive Opinion on Myozyme from CHMP
CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that the Committee for Medicinal Products for Human Use (CHMP) has